<DOC>
	<DOCNO>NCT00317798</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , antithymocyte globulin may stimulate immune system different way stop cancer cell grow . Sirolimus may stop growth cancer cell block enzymes need cell growth . It may also prevent reduce side effect antithymocyte globulin . Giving antithymocyte globulin together sirolimus may kill cancer cell . PURPOSE : This phase I trial study side effect best dose antithymocyte globulin give together sirolimus treat patient relapsed multiple myeloma .</brief_summary>
	<brief_title>Antithymocyte Globulin Sirolimus Treating Patients With Relapsed Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety tolerability , term clinical laboratory toxicity , anti-thymocyte globulin ( ATG ) combine sirolimus patient relapse multiple myeloma . - Determine dose-limiting toxicity regimen patient . - Determine maximum tolerate dose ATG administer sirolimus patient . Secondary - Determine clinical activity regimen , term measurability improvement clinical benefit , patient . - Assess patient sensitivity CD 138^-positive myeloma cell ATG prior treatment . - Determine pharmacokinetics , term ATG level blood bone marrow , patient . - Assess binding capability ATG bone marrow resident myeloma cell . - Determine ATG-resistant clone emerge treatment . OUTLINE : This open-label , pilot , dose-escalation study anti-thymocyte globulin ( ATG ) . Patients receive ATG IV 6-12 hour 4 , 6 , 8 day oral sirolimus daily day 1-30 absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos ATG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . Bone marrow aspirate blood sample collect baseline periodically study treatment drug sensitivity pharmacokinetic study . After completion study treatment , patient follow every 3 week 2 month monthly thereafter . PROJECTED ACCRUAL : A total 18 patient accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Previously diagnose multiple myeloma ( MM ) base standard criterion Soft tissue ( bone ) plasmacytoma allow Measurable disease , meet follow criterion : Monoclonal population plasma cell bone marrow Quantifiable serum and/or urine monoclonal protein ( i.e. , generally , exclusively , IgG &gt; 1 g/dL , IgA &gt; 0.5 g/dL , urine lightchain excretion ≥ 200 mg/24 hour ) Steroidrefractory disease , define less minimum response prior highdose glucocorticoid therapy Minimal response require follow criterion : 2549 % reduction level serum monoclonal paraprotein maintain ≥ 6 week 5089 % reduction 24hour urinary lightchain excretion , still &gt; 200 mg/24 hour , maintain ≥ 6 week 2549 % reduction size soft tissue plasmacytoma ( clinically CT scan MRI ) No increase size number lytic bone lesion Highdose glucocorticoid therapy define 480 mg dexamethasone ( equivalent ) alone part vincristine , doxorubicin , dexamethasone regimen Must undergone autologous transplantation OR receive ≥ 2 conventional line therapy Currently require therapy progressive disease , indicate follow criterion : 25 % increase paraprotein Development new progression preexist lytic bone lesion soft tissue plasmacytoma Hypercalcemia attributable cause Relapse complete remission No nonsecretory MM PATIENT CHARACTERISTICS : Zubrod performance status 02 34 allow , opinion investigator , secondary MMrelated bone pain Life expectancy ≥ 3 month Creatinine ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Bilirubin ≤ 1.5 time ULN Calcium &lt; 14 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative Hepatitis B surface antigen hepatitis C antibody negative No known history allergy rabbit proteins No history cardiac amyloidosis No poorly control hypertension , diabetes mellitus , coronary artery disease , serious medical psychiatric illness No myocardial infarction within past 6 week No New York Heart Association class III IV heart failure No uncontrolled angina No severe uncontrolled ventricular arrhythmia No evidence acute ischemia active conduction system abnormality electrocardiogram No active systemic infection require treatment unless adequately control appropriate antimicrobial therapy ( e.g. , treated central line infection ) No acute viral illness No pathologic fracture symptomatic hyperviscosity No prior malignancy except adequately treat basal cell squamous cell skin cancer , cervical cancer situ , cancer diseasefree status ≥ 3 year PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 8 week since prior immunotherapy antibody therapy At least 4 week since prior major surgery ( except kyphoplasty ) At least 3 week since prior conventional chemotherapy radiotherapy MM At least 3 week since prior bortezomib , thalidomide , clarithromycin MM No prior antithymocyte globulin No concurrent radiotherapy No concurrent antineoplastic therapy know activity MM , include clarithromycin No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>drug/agent toxicity tissue/organ</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>